Hjem › Myelodysplastiske syndromer › Tennessee
Kliniske studier for Myelodysplastiske syndromer i Tennessee
15 studier for Myelodysplastiske syndromer søker deltakere på steder i Tennessee.
Byer i Tennessee
Offisiell studietekst (engelsk)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT05564390A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Tennessee Oncology, PLLC, Nashville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 18. sep. 2026 · NCT07422480Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
- Sarah Cannon Center for Blood Cancer at TriStar Centennia, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT06846606The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- East Tennessee Childrens Hospital, Knoxville
- Saint Jude Children's Research Hospital, Memphis
- The Children's Hospital at TriStar Centennial, Nashville
- og 1 flere
RekruttererFase 1/2
Opp til 22 år · Alle kjønn · Oppdatert 25. aug. 2026 · NCT04726241A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Tennessee Cancer Specialists, Knoxville
- Vanderbilt University Medical Center, Nashville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 21. aug. 2026 · NCT06499285A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
- Baptist Clinical Research Institute, Memphis
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 21. aug. 2026 · NCT04419649Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
- Baptist Health Care Corporation, Memphis
- Vanderbilt University/Ingram Cancer Center, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 19. aug. 2026 · NCT06399640Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Vanderbilt University, Ingram Cancer Center, Nashville
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 7. jul. 2026 · NCT07216443Investigation of the Genetics of Hematologic Diseases
- St. Jude Children's Research Hospital, Memphis
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 9. jun. 2026 · NCT02720679A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Vanderbilt University Medical Center, Nashville
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 30. apr. 2026 · NCT04256317A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- TriStar Centennial Medical Center, Nashville
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 24. mar. 2026 · NCT04988555Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
- St. Jude Children's Research Hospital, Memphis
RekruttererFase 2
Alder 10 til 30 · Alle kjønn · Oppdatert 4. des. 2025 · NCT05194397SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
- Sarah Cannon Research Institute, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 24. sep. 2025 · NCT06501196HPC Offered for PRESERVE Expansion
- Tristar Centennial Medical Center, Nashville
RekruttererObservasjonsstudie
Alder 12 til 80 · Alle kjønn · Oppdatert 28. aug. 2025 · NCT07145411Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.